Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

ly significant difference between treatment outcomes of the vaccinated and non-vaccinated groups.

Based on the success of preclinical studies, the PATH Malaria Vaccine Initiative (MVI) and Inovio announced a follow-on collaboration to advance Inovio's malaria DNA vaccine and electroporation technology into a phase I/IIa clinical trial in 2014. Established at PATH through an initial grant from the Bill & Melinda Gates Foundation, MVI's mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world. 

Corporate DevelopmentInovio continues to advance discussions with large pharmaceutical companies with the goal of securing strategic partnerships to advance the development of SynCon® vaccines.

Subsequent to the quarter, Inovio and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) received a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of Inovio's next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.

Inovio was recognized with Vaccine Industry Excellence (ViE) Awards for "Best Therapeutic Vaccine" and "Best Early Stage Biotech" at the World Vaccine Congress. The ViE Awards recognize outstanding vaccine advancements and achievements of vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown i
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... first participant in its Phase 1/2 clinical trial ... chronic unilateral Achilles tendinosis, has been enrolled and ... intra-tendon ultrasound-guided injections. RCT-01 is comprised of non-bulbar ...
(Date:6/30/2015)... ONTARIO (PRWEB) , ... June 30, 2015 , ... ... studies prior to launching SmartArch — a revolutionary new archwire that allows orthodontists ... provide further clinical evidence of the efficacy of SmartArch. “We’re thrilled about taking ...
(Date:6/29/2015)... 30, 2015   Pharnext SAS today announced that ... the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented ... Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress ... 27 - July 2, 2015. At Poster Viewing ... 1, 5p.m. to 7p.m. EDT: Poster 23: ...
(Date:6/29/2015)... June 29, 2015 BioNano Genomics, Inc., the ... research institutes, announced today that a collaboration led by ... in the creation of the first comprehensive analysis of ... molecule methods for sequencing and genome mapping. This study, ... comprehensive analysis of the contiguous diploid human genome assembly ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3
... OrganicGardenGrower.com Introduces ... and fun. , ... (PRWEB) October 19, 2009 -- It,s no longer a complicated process for anyone to grow ... the demand for healthy, fresh fruits and veggies grow, so has the demand of individuals ...
... 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: LTUS) ("Lotus" ... and licensed national seller of pharmaceutical,products in the People,s Republic ... Lotus,s priorities for the balance of 2009 are, ... do for its most valuable customers, ...
... EMERYVILLE, Calif., Oct. 19 Neurobiological Technologies, Inc. (Nasdaq: ... to the NASDAQ Stock Market LLC ("NASDAQ") that NTI intends ... Commission ("SEC") on or about October 28, 2009 to effect ... NTI,s stockholders approve the dissolution of the company pursuant to ...
Cached Biology Technology:The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 2The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 3Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 2Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 3Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 4
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und ... QGEN ; Frankfurt Prime Standard: QIA) hat heute in ... Produktlinie Investigator ® für ... Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... vary greatly in their dependence on the global food ... its most common food in its regional hinterland, while ... Copenhagen hinterland produces less than half of the consumption ... researchers have mapped the food systems of capital cities, ...
... Sciences faculty members whose research has resulted in ... startup companies have been named fellows of the ... Wittwer, M.D., Ph.D., professor of pathology and research ... of internal medicine and chief of the Division ...
... 11, 2013) In a study of older mice, wolfberries ... protection against the flu virus. The research, led by scientists ... Aging (USDA HNRCA) at Tufts University, suggests the wolfberry may ... role in the ability of the immune system to defend ...
Cached Biology News:Scientists map food security and self-provision of major cities 2Scientists map food security and self-provision of major cities 3Researchers named to National Academy of Inventors 2Researchers named to National Academy of Inventors 3Researchers named to National Academy of Inventors 4Older mice fed wolfberries show reduced risk for flu virus with vaccine 2
...
... feature a dual strength adhesive system which facilitates ... The adhesives on either side of the frame ... to the glass has an easy release adhesive ... forms a stronger bond. This means that when ...
... Cultures (ECACC) has been offering training courses ... institutes for over seven years. We offer ... candidates to cell culture and a Level ... areas such as planning and management of ...
... cover slips for in situ hybridization,in ... on glass slides., Constant probe ... not adsorb probes. , Ready-to-use-Hybri-slips do ... , Avoid RNA degradation-Hybri-slips are supplied ...
Biology Products: